Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Aicuris Gmbh + Co. Kg.

Bayer Schering Pharma Ag

Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Aicuris Anti-infective Cures Gmbh

Aic246 Ag & Co. Kg

Bayer Aktiengeselischaft

Aicuris Gmbh & Co. Hk

Dieter Lang

Frank Wunder

Johannes-Peter Stasch

Kerstin Henninger

Holger Zimmermann

Gorden Redlich

Markus Follmann

Rolf Grosser

Achim Feurer

Rudolf Schohe-Loop

Adrian Tersteegen

Alexandros Vakalopoulos

Walter Hübsch

Elke Stahl

Mario Jeske

Karl-Heinz Schlemmer

Michael Hahn

Hanna Tinel

Tobias Wunberg

Peter Nell

Andreas Knorr

Alexander Straub

Carsten Schmeck

Klaus Dembowsky

Joachim Luithle

Raimund Kast

Joerg Keldenich

Judith Baumeister

Cristina Alonso-Alija

Stefan Weigand

Elisabeth Perzborn

Nils Griebenow

Joachim Mittendorf

Eva-Maria Becker

Hartmut Schirok

Peter Kolkhof

Christina Erb

Anja Buchmüller

Marja Van Kampen

Daniel Meibom

Frank-Thorsten Hafner

Franz-Josef Van Der Staay

Katrin Schnizler

Volkhart Min-Jian Li

Thomas Lampe

Kai Thede

Stefan Heitmeier

Philipp Buchgraber

Frank-Gerhard Böβ

Marcus Bauser

Frank Süβmeier

Klaus Münter

Alexander Hillisch

Jörg Keldenich

Heike Heckroth

Martina Delbeck

Mark Jean Gnoth

Ingo Flamme

Chantal Fuerstner

Ulrich Rosentreter

Katja Zimmermann

Martin Hendrix

Christoph Gerdes

Jens Ackerstaff

Elisabeth Pook

Tobias Marquardt

Barbara Albrecht-Küpper

Dagmar Karthaus

Mario Lobell

Rudy Schreiber

Heike Gielen-Haertwig

Jens-Kerim Ergüden

Peter Fey

Thomas Schenke

Gerhard Siemeister

Pierre Wasnaire

Ulf Bömer

Joachim Schuhmacher

Thomas Rölle

Klemens Lustig

Wahed Ahmed Moradi

Susanne Röhrig

Arnold Paessens

Bernd Riedl

Heinrich Meier

Niels Lindner

Axel Kretschmer

Britta Olenik

Friederike Stoll

Heiko Schirmer

Hartmut Beck

Stephan Bartel

Chantal Fürstner

Ningshu Liu

Joachim Telser

Stefan Golz

Jens Hoffmann

Michael Härter

Lisa Dietz

Kirstin Petersen

The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, preferably 480 to 2000 μg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid in form of mono hydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.

Treatment of cardiopulmonary disorders

The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Substituted dihydroquinazolines

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted oxopyridine derivatives

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

Substituted piperidinyl tetrahydroquinolines

This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides

The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.

Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

5-aminotetrahydroquinoline-2-carboxylic acids and their use

The present invention relates to novel 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular and renal diseases.

Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines

Growing community of inventors

Velbert, Germany

Dieter Lang